Product image of Mirabegron Glenmark (Mirabegron) supplied by GNH India

Mirabegron Glenmark

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Glenmark (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms—including urinary urgency, frequency, and urge incontinence—in adult patients and is marketed in the European Union.

GNH India supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, ensuring consistent product quality, regulatory compliance and reliable logistics for global healthcare providers through established distribution networks.

Manufacturer / TM Owner

Glenmark Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function in patients with overactive bladder.

  • Overactive bladder: reduces urinary urgency and frequency by increasing bladder capacity.
  • Urinary urgency: lessens the sudden, strong need to void.
  • Frequency: decreases the number of daytime voids.
  • Urge incontinence: helps prevent involuntary leakage associated with urgency.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors located on the detrusor smooth muscle of the urinary bladder. This activation stimulates cyclic AMP production, leading to relaxation of the detrusor muscle during the storage phase, thereby increasing functional bladder capacity and reducing involuntary contractions that cause urgency and incontinence.

Side Effects

Common Side Effects

  • Hypertension: elevated blood pressure observed in some patients.
  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Urinary tract infection: increased susceptibility to bacterial infection of the urinary system.
  • Headache: mild to moderate head pain.
  • Constipation: reduced bowel motility.
  • Dry mouth: decreased salivation.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Severe hypertension: markedly high blood pressure requiring medical attention.
  • Tachycardia: rapid heart rate.
  • Angioedema: swelling of the face, lips, or throat.
  • Myocardial infarction: rare occurrence of heart attack.
  • Anaphylaxis: severe allergic reaction requiring immediate care.

Precautions & Warnings

Mirabegron should be used with caution in the following situations:

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: assess liver function before initiating treatment.
  • Hypertension: regularly check blood pressure during therapy.
  • Concomitant anticholinergics: evaluate for additive anticholinergic effects.
  • Pregnancy: safety not established; use only if potential benefit justifies risk.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Mirabegron may interact with several drug classes. Review the following interactions before prescribing:

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors: may increase mirabegron plasma concentrations.
  • Norepinephrine reuptake inhibitors: heightened risk of hypertension.
  • Antihypertensive agents: potential reduction in blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

  • Diuretics: additive effect on blood pressure control.
  • Anticholinergics: possible reduction in therapeutic benefit for bladder symptoms.
  • Beta‑blockers: potential pharmacodynamic interaction affecting cardiovascular response.

Frequently Asked Questions

Mirabegron Glenmark is prescribed to manage symptoms of overactive bladder, including urinary urgency, increased frequency of urination, and urge incontinence. It helps improve bladder storage capacity, reducing the need for frequent or sudden trips to the bathroom.

Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation relaxes the muscle during the storage phase, increasing bladder capacity and decreasing involuntary contractions that cause urgency and leakage.

The dose of mirabegron is individualized by the prescribing clinician based on the patient’s condition, renal and hepatic function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth or constipation that are common with anticholinergic agents. It may be used alone or in combination with anticholinergics to enhance symptom control.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from moisture and direct light, and keep it out of reach of children.

Mirabegron Glenmark is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe hypertension, urinary retention, tachycardia, angioedema, myocardial infarction and rare cases of anaphylaxis. Patients should seek immediate medical attention if they experience symptoms such as a sudden rise in blood pressure, difficulty urinating, rapid heartbeat, swelling of the face or throat, or signs of an allergic reaction.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT